We would like to congratulate Dr. Nirasha Ramchurren from the Fred Hutchinson Cancer Research Center whose submission has been selected as the winner of our 2020 Grant Program. All grant submissions were judged both on scientific merit and how well the proposed study would benefit from the capabilities offered by the Ionic® Purification System. In her submission, Dr. Ramchurren describes how she wants to extract RNA from skin melanoma FFPE samples for gene expression profiling to interrogate longitudinal biopsies from the Cancer Immunotherapy Trials Network (CITN-13). The study will explore the immune milieu of the tumor microenvironment for correlates of response in cutaneous T-cell lymphoma (CTCL) patients. “We hope to greatly expand and refine our internal technologies and assays for gene expression profiling analysis of FFPE samples for all of our studies,” says Dr. Ramchurren. “The CITN has an extensive and expanding collection of valuable and unique biopsy specimens with extensive clinically annotated information across all of our immunotherapy trials. We need reliable and efficient RNA purification methods that allow us to extract the most information possible from these precious samples.” Purified RNA will be assayed for gene expression on the NanoString nCounter System using the Pan Cancer IO 360 panel at the Fred Hutch Core Facility.
Dr. Nirasha Ramchurren, Fred Hutchinson Cancer Immunotherapy Trials Network
As the Grant Program winner Dr. Ramchurren will be able to purify RNA from up to one hundred FFPE samples using the Ionic® Purification System and Ionic® FFPE to Pure RNA Kits at no cost. Regardless of how challenging or limited the samples may be, we are confident our technology will provide sufficient yield and quality for this important study.